Positive Phase 3 Results for Epcoritamab Combo in DLBCL

Key Facts

1Phase 3 EPCORE DLBCL-4 trial showed epcoritamab combination reduced disease progression risk by up to 60% in relapsed/refractory DLBCL.

2Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide demonstrating statistically significant improvement in progression-free survival.

In a development that bolsters treatment options for lymphoma, AbbVie and Genmab announced positive Phase 3 results from the EPCORE DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide. The data showed a statistically significant improvement in progression-free survival, reducing the risk of disease progression by up to 60% compared to standard of care.

Per market data, AbbVie shares closed at $251.52 (June 26, 2026), while Genmab closed at $26.12. The positive results strengthen the companies' positions in the competitive oncology market, particularly for relapsed/refractory DLBCL.

Investors are now watching for potential regulatory submissions to the FDA and other authorities, which could drive further upside. The market will also focus on full data disclosures and commercialization plans.